Presentation: Novel T cell antigen discovery technology and malaria vaccines

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

please check before submitting

Mobile number:

What is your role?

Subscribe to VaccineNation Newsletter?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

Why a Malaria Vaccine? The 2011 WHO World Malaria Report estimated 655,000 malaria deaths and 216 million clinical cases in 2010 alone. Malaria remains a global problem, despite the use of preventive actions, such as the use of nets, anti-malarial drugs and insecticides. Malaria Prevention is a top priority and subsequently, so is the development of a vaccine. Dr Jessica Flechtner, Vice President Research at Genocea presented at the World Vaccine Congress 2012 in Washington on the development of a malaria vaccine, in particular on the complexities involved.

Why not download the full presentation and discover more about malaria vaccine, for example more on how Novel T cell antigen discovery technology has provided momentum to the research:

• Human immune response profiling and vaccine development
• Novel vaccine design approach – what does this mean in the case of malaria?
• Protective antigen identification – the way forward

Presentation: Novel T cell antigen discovery technology and malaria vaccines

information we require

please check before submitting